Diaz Mora Prameyllawati on Going Beyond the Price Tag for Gene Therapies in Hemophilia
Diaz Mora Prameyllawati, PhD Candidate at Erasmus MC, shared on LinkedIn:
”Beyond the price tag of gene therapy
Gene therapies are often discussed in terms of their high price, which can range from €1 to €3.5 million per individual.
In our latest study on gene therapy for hemophilia, we went beyond the price tag and focused on what it actually takes to deliver these therapies in clinical practice.
To support successful and sustainable implementation, we developed:
- A detailed process map covering all care activities from site preparation to follow-up.
- Comprehensive cost catalogs capturing every component of care, enabling other hospitals and countries to estimate their own delivery costs.
These tools aim to inform economic evaluations, reimbursement discussions, and the real-world implementation of gene therapy for hemophilia.
More details in our latest publication.
This work was made possible through the support of the SYMPHONY consortium.
I sincerely thank all participating healthcare professionals for their openness and valuable insights during the interviews, as well as my supervisors and co-authors for their guidance and collaboration throughout the study.”
Read the full article here.
Article: Health care resources and costs associated with delivering gene therapy for hemophilia in clinical practice
Authors: Diaz M. Prameyllawati, Caroline M.A. Mussert, Martijn A.H. Oude Voshaar, Hester F. Lingsma, Marjon H. Cnossen, Michiel Coppens, Karina Meijer, Paul R. van der Valk, Frank W.G. Leebeek, Renske M.T. ten Ham

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 13, 2026, 16:17Wolfgang Miesbach: Gene Therapy Shows Promising Early Results in Adolescents With Hemophilia B at ISTH 2026
-
Jul 13, 2026, 16:06Dino Mehic: Honored to Receive the ISTH Early Career Top Reviewer Awards
-
Jul 13, 2026, 16:01Advancing DIC Diagnosis in Cirrhosis Through Disease-Specific Risk Stratification – JTH
-
Jul 13, 2026, 15:52Joshua Muia: Presenting Our Research on ADAMTS13/VWF Dysregulation in Sepsis at ISTH 2026
-
Jul 13, 2026, 15:42Marc Carrier: Important New Data From the API-CAT Trial on Recurrent VTE During Extended Apixaban Therapy
-
Jul 13, 2026, 15:23Akshat Jain: 5 Key Clinical Takeaways from ISTH 2026
-
Jul 13, 2026, 15:15Alfonso J. Tafur: Insights on Periprocedural DOAC Management in Atrial Fibrillation at ISTH 2026
-
Jul 13, 2026, 14:42Bruno Pougault: The Global Momentum Behind Innovation in Thrombosis and Hemostasis
-
Jul 13, 2026, 14:34Julie Vassart: Optimizing DOAC Detection in an Evolving Anticoagulant Landscape at ISTH 2026